NMTC
NeuroOne Medical Technologies CorporationNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
6.52
P/S
4.83
EV/EBITDA
-5.68
DCF Value
$-53.82
FCF Yield
-14.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.9%
Operating Margin
-87.7%
Net Margin
-78.3%
ROE
-119.9%
ROA
-79.6%
ROIC
-102.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.9M | $-1.4M | $-0.03 |
| Q4 2025 | $2.7M | $-1.6M | $-0.04 |
| FY 2025 | $12.1M | $-3.6M | $-0.09 |
| Q3 2025 | $1.7M | $-1.5M | $-0.03 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.58
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.